Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada, the United States, and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Health Inc. and changed its name to Grey Matters Health Inc. in April 2026. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.…
Grey Matters Health achieves medicare and medicaid enrollment for Florida NovaScan Clinic
Grey Matters Health (CNSX: GREY) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.2950 CAD on 20 November 2026, down 63.1% over 52 weeks. Its 52-week range is 0.2800 CAD to 0.8500 CAD: the price is 65.3% below the high and 5.4% above the low.
Its market capitalisation is 2.84M CAD.
Grey Matters Health reports return on equity of -63.7% and an operating margin of 0.0%.
Its debt exceeds its cash by 737.14K CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.